

1600

1614515

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

1400

In Re Application Of: Jose Repolles Moliner, et al.

Serial No.

09/912,164

Filing Date

July 24, 2001

Examiner

Unknown

Group Art Unit

Title: S-NITROSONIOLAS AGENTS FOR THE TREATMENT OF CIRCULATORY DYSFUNCTIONS

Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
14797

In Re Application Of: Jose Repolles Moliner, et al.


Serial No.  
09/912,164

Filing Date  
July 24, 2001

Examiner  
Unknown

Group Art Unit  
2954

Title: S-NITROSOHOLISAS AGENTS FOR THE TREATMENT OF CIRCULATORY DYSFUNCTIONS



RECEIVED  
DEC 15 2001  
TECH CENTER 1600/2900  
DEC 07 2001

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. \_\_\_\_\_) on \_\_\_\_\_ (Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on November 28, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

Janet Grossman  
Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

\_\_\_\_\_  
Signature

Dated: November 28, 2001

Leslie S. Szivos  
Registration No. 39,394

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

CC:

70.14  
A 2111  
RECEIVED  
RECEIVED  
TECH CENTER 1600/2900  
PATENT  
TECH CENTER 1600/2900  
2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jose Repolles Molina, et al.

Examiner: Unknown

Serial No.: 09/912,164

Art Unit: 1614

Filed: July 24, 2001

Docket: 14797

For: S-NITROSOTHIOLS AS AGENTS FOR  
THE TREATMENT OF CIRCULATORY  
DYSFUNCTIONS

Dated: November 28, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. U.S. Patent No. 4,137,236, issued January 30, 1979 to Rodriguez, et al.;
2. U.S. Patent No. 4,271,172, issued June 2, 1981 to Rodriguez, et al.;
3. U.S. Patent No. 5,968,911, issued October 19, 1999 to Lawson, et al.;
4. International Patent Application No. WO 95/12394, issued May 11, 1995;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on November 28, 2001.

Dated: November 28, 2001

  
Janet Grossman

5. International Patent Application No. WO 93/09806, issued May 27, 1993;
6. International Patent Application No. WO 96/16645, issued June 6, 1996;
7. European Patent Application No. EP 0 412 699 B1, issued February 13, 1991;
8. Radomski, et al., "S-nitroso-glutathione inhibits platelet activation *in vitro* and *in vivo*," Br. J. Pharmacol., (1992), 107, pp. 745-749;
9. Golino, et al., "Endothelium-Derived Relaxing Factor Modulates Platelet Aggregation in an In Vivo Model of Recurrent Platelet Activation," Circulation Research, Vol. 71, No. 6, (1992), pp. 1447-1456;
10. Lawson, et al., "Pharmacology of a Human Dopamine D<sub>4</sub> Receptor Expressed in HEK293 Cells," Meth Find Exp Clin Pharmacol, (1994), 16(5), pp. 303-307;
11. Kaiser, et al., "Color Test for Detection of Free Terminal Amino Groups in the Solid-Phase Synthesis of Peptides," Anal. Biochem., 34, (1970), pp. 595-598;
12. Furchgott, "Bioassays with Isolated Vascular Tissue for Endothelium-derived Relaxing Factor, Nitric Oxide and Nitric Oxide Donors," Feelisch & Stamler Eds., John Wiley & Sons, Chichester, England, (1996), pp. 567-581;
13. Trongvanichnam, et al., "Effects of Chronic Oral Administration of Isosorbide Dinitrate on In Vitro Contractility of Rat Arterial Smooth Muscle," Jpn. J. Pharmacol., (1996), 71, pp. 167-173;
14. Salas, et al., "Endothelium-independent relaxation by 17- $\alpha$ -estradiol of pig coronary arteries," Eur. J. Pharmacol., (1994), 258, pp. 47-55;
15. Loscalzo, et al., "Platelet Bioassays of Nitric Oxide and Related Congeners," Feelisch & Stamler Eds., John Wiley & Sons, Chichester, England, (1996), pp. 583-591;
16. Radomski, et al., "Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets," Br. J. Pharmacol., (1987), 92, pp. 181-187;
17. Moro, et al., "Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine of human platelets," Br. J. Pharmacol., (1994), 112, pp. 1071-1076;


18. Moro, et al., "cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase," Proc. Nat. Acad. Sci. USA, (1996), 93, pp. 1480-1485;
19. Butler, et al., "Synthesis, Decomposition, and Vasodilator Action of Some New S-Nitrosated Dipeptides," NITRIC OXIDE: Biology and Chemistry, Vol. 2, No. 3, pp. 193-202, (1998);
20. Humphrey, et al., "Preparation of Some Novel S-Nitroso Compounds as Potential Slow-release Agents of Nitric Oxide *in vivo*," J. Chem. Co., Perkin Trans. 1, (1994), pp. 797-805;
21. Mathews, et al., "Biological Activity of S-Nitrosothiols: The Role of Nitric Oxide," J. Pharmacol. and Exp. Therapeutics, 267(8), (1993), pp. 1529-1537; and
22. Dicks, et al., "Identification of  $\text{Cu}^+$  as the effective reagent in nitric oxide formation from S-nitrosothiols (RSNO)," J. Chem. Soc., PerkinTrans. 2, (1996), pp. 481-487.

Applicant is submitting copies of the above-cited references. All of the references listed on Form PTO-1449 are in the English language; thus a concise explanation of the cited references required by 37 C.F.R. §1.98(a)(3) is not necessary.

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herewith may be material to the examination of the present application as defined under 37 C.F.R. §1.56. This statement is not intended to represent that a search has been performed or that no other art than that identified herein exists.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no petition, certification or fee is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Leslie Szivos", followed by a horizontal line.

Leslie S. Szivos  
Registration No. 39,394

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

LSS:gc